1. mRNA vaccination in people over 80 years of age induces strong ... - eLife
29 sep 2021 · The mRNA vaccine platform delivers strong humoral immunity in people up to 96 years of age and retains broad efficacy against the P.1 variant of concern.
The BNT162b2 mRNA COVID-19 vaccine is highly effective at generating immune responses in people over the age of 80 years and provides good cross neutralization of the P.1 gamma variant of concern.
2. POLITICO EU Confidential: Facebook's Nick Clegg — Vaccine ...
Vaccine patent waivers: Why are Angela Merkel and other EU leaders so cool on U.S. President Joe Biden's surprise proposal to waive intellectual property rights ...
Presented by Shell. By Cristina Gonzalez, Andrew Gray and Paul Dallison PRESENTED BY Listen to the podcast on Spotify | Apple | Google | Simplecast | Stitcher | View in your browser Welcome to EU C…
3. [PDF] Delivering the COVID-19 vaccine across London | UCLPartners
This report was written by Sophie Bulmer, Emma Mordaunt, Rachel Penniston, Mark Biddle and. Dr Jenny Shand from UCLPartners in collaboration with colleagues ...
4. Short-term safety of COVID-19 mRNA vaccines with respect to all-cause ...
There have been concerns about COVID-19 vaccination safety among frail older individuals. We investigated the relationship between COVID-19 mRNA vaccination ...
There have been concerns about COVID-19 vaccination safety among frail older individuals. We investigated the relationship between COVID-19 mRNA vaccination and mortality among individuals aged ≥ 70 years and whether mortality varies across four ...
5. Tom Parry on LinkedIn: Very pleased that my long read article on ...
7 nov 2024 · Very pleased that my long read article on unvaccinated children in Ethiopia needlessly dying from preventable diseases was recently ...
Very pleased that my long read article on unvaccinated children in Ethiopia needlessly dying from preventable diseases was recently shortlisted for two awards:…
6. Study shows new RSV vaccine for pregnant women could prevent an ...
2 sep 2024 · News. Study shows new RSV vaccine for pregnant women could prevent an estimated 900 babies being admitted to hospitals in London every year.
The Respiratory Syncytial Virus (RSV) vaccine, which is being rolled out this week across the capital, could prevent an estimate of around 900 babies being admitted to hospitals in London every year. RSV is highly contagious and while it causes mild, cold-like symptoms in most cases, it can be serious and even life-threatening to babies, […]
7. Herpes zoster vaccine and the risk of stroke - BMJ Public Health
This study is based in part on data from the Clinical Practice. Research Datalink obtained under licence from the UK. Medicines and Healthcare.
8. Recent development of oral vaccines (Review) - Spandidos Publications
22 mrt 2024 · Kurup VM and Thomas J: Edible vaccines: Promises and challenges. Mol ... Sharpe S, Fooks A, Lee J, Hayes K, Clegg C and Cranage M ...
Oral immunization can elicit an effective immune response and immune tolerance to specific antigens. When compared with the traditional injection route, delivering antigens via the gastrointestinal mucosa offers superior immune effects and compliance, as well as simplicity and convenience, making it a more optimal route for immunization. At present, various oral vaccine delivery systems exist. Certain modified bacteria, such as Salmonella, Escherichia coli and particularly Lactobacillus, are considered promising carriers for oral vaccines. These carriers can significantly enhance immunization efficiency by actively replicating in the intestinal tract following oral administration. The present review provided a discussion of the main mechanisms of oral immunity and the research progress made in the field of oral vaccines. Additionally, it introduced the advantages and disadvantages of the currently more commonly administered injectable COVID‑19 vaccines, alongside the latest advancements in this area. Furthermore, recent developments in oral vaccines are summarized, and their potential benefits and side effects are discussed.
9. Vaccine adjuvants: mechanisms and platforms - Nature
19 jul 2023 · When Clegg et al. used GLA-SE as an adjuvant for the H5N1 subunit ... Thomas, C., Rawat, A., Hope-Weeks, L. & Ahsan, F. Aerosolized PLA ...
Adjuvants are indispensable components of vaccines. Despite being widely used in vaccines, their action mechanisms are not yet clear. With a greater understanding of the mechanisms by which the innate immune response controls the antigen-specific response, the adjuvants’ action mechanisms are beginning to be elucidated. Adjuvants can be categorized as immunostimulants and delivery systems. Immunostimulants are danger signal molecules that lead to the maturation and activation of antigen-presenting cells (APCs) by targeting Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs) to promote the production of antigen signals and co-stimulatory signals, which in turn enhance the adaptive immune responses. On the other hand, delivery systems are carrier materials that facilitate antigen presentation by prolonging the bioavailability of the loaded antigens, as well as targeting antigens to lymph nodes or APCs. The adjuvants’ action mechanisms are systematically summarized at the beginning of this review. This is followed by an introduction of the mechanisms, properties, and progress of classical vaccine adjuvants. Furthermore, since some of the adjuvants under investigation exhibit greater immune activation potency than classical adjuvants, which could compensate for the deficiencies of classical adjuvants, a summary of the adjuvant platforms under investigation is subsequently presented. Notably, we highlight the different action mechanisms and immunological prop...
10. Association of bovine respiratory disease or vaccination with ...
... Clegg, Tracy A., Earley, Bernadette, O'Neill, Rónan G., Johnston, Dayle, Gilmore, John, Nosov, Mikhail, McElroy, Máire C., Inzana, Thomas J., and Cassidy ...
Abstract OBJECTIVE To investigate the association of bovine respiratory disease (BRD) or vaccination with serologic response in calves. ANIMALS 94 Holstein calves. PROCEDURES To assess the association between BRD and antibody titers, 38 calves < 3 months old that were treated for BRD were matched with 38 untreated calves. To investigate the effect of vaccination on antibody titers, 24 calves were randomly assigned to be vaccinated against bovine respiratory syncytial virus (BRSV), bovine viral diarrhea virus types 1 and 2, bovine herpesvirus type 1 (BHV1), and parainfluenza virus type 3 at 2 weeks of age (n = 6), 5 weeks of age (6), and both 2 and 5 weeks of age (6) or were assigned to be unvaccinated controls (6). Blood samples were obtained at I, 2, 5, and 12 weeks for determination of serum neutralization antibody titers against the vaccine viruses, bovine coronavirus, and Mannheimia haemolytica. Antibody rates of decay were calculated. RESULTS Calves with initial antibody titers against BRSV < 1:64 that were treated for BRD had a slower rate of anti-BRSV antibody decay than did similar calves that were not treated for BRD. Calves with high initial antibody titers against BRSV and BHV1 had lower odds of BRD than did calves with low initial antibody titers against those 2 pathogens. Vaccination at 2 or 5 weeks of age had no effect on the rate of antibody decay. CONCLUSIONS AND CLINICAL RELEVANCE Clinical BRD and the serologic response of dairy calves were associated with in...
11. Frontiers | Staphylococcus aureus Vaccine Research and Development
Staphylococcus aureus Vaccine Research and Development: The Past, Present and Future, Including Novel Therapeutic Strategies. Jonah Clegg, Jonah Clegg1,2 ...
Staphylococcus aureus is one of the most important human pathogens worldwide. Its high antibiotic resistance profile reinforces the need for new intervention...
12. GLA-AF, an Emulsion-Free Vaccine Adjuvant for Pandemic Influenza
Thus, GLA-AF is a potent emulsion-free adjuvant that warrants consideration for pandemic influenza vaccine development. Citation: Clegg ... Thomas K, Phalipon A, ...
The ongoing threat from Influenza necessitates the development of new vaccine and adjuvant technologies that can maximize vaccine immunogenicity, shorten production cycles, and increase global vaccine supply. Currently, the most successful adjuvants for Influenza vaccines are squalene-based oil-in-water emulsions. These adjuvants enhance seroprotective antibody titers to homologous and heterologous strains of virus, and augment a significant dose sparing activity that could improve vaccine manufacturing capacity. As an alternative to an emulsion, we tested a simple lipid-based aqueous formulation containing a synthetic TLR4 ligand (GLA-AF) for its ability to enhance protection against H5N1 infection. GLA-AF was very effective in adjuvanting recombinant H5 hemagglutinin antigen (rH5) in mice and was as potent as the stable emulsion, SE. Both adjuvants induced similar antibody titers using a sub-microgram dose of rH5, and both conferred complete protection against a highly pathogenic H5N1 challenge. However, GLA-AF was the superior adjuvant in ferrets. GLA-AF stimulated a broader antibody response than SE after both the prime and boost immunization with rH5, and ferrets were better protected against homologous and heterologous strains of H5N1 virus. Thus, GLA-AF is a potent emulsion-free adjuvant that warrants consideration for pandemic influenza vaccine development.
13. Lead NHS vaccine nurse and frontline staff among health service honours
31 dec 2022 · A number of top nurses receive honours, with MBEs for Elspeth Jane Clegg ... Thomas's NHS Foundation Trust. Other NHS staff recognised ...
Dozens of NHS staff have been recognised in this year’s New Year Honours list ahead of the health service’s 75th birthday. The honours have been awarded to an array of NHS staff including front line doctors and nurses, hospital volunteers and leaders in the world beating Covid vaccination programme. Leading nurse, Jennifer Hall, director of […]
14. [PDF] Strategic Advisory Group of Experts (SAGE) on Immunization Hybrid ...
26 sep 2024 · Thomas. ALTHAUS. Health Affairs. Directorate of Monaco. Public Health Medical ... Clegg. AstraZeneca. Group Director, Clinical. Pharmacology ...
15. [PDF] Measles, Mumps, and Rubella — Vaccine Use and Strategies ... - CDC
Vaccine adverse events: causal or coincidental [comment]. Lancet. 1998;351:611–2. 164. Feeney M, Clegg A, Winwood P, Snook J. A case-control study of measles ...
16. Uptake of COVID-19 vaccinations amongst 3433483 children and ...
10 sep 2024 · ... Clegg, Sarah E Rodgers, Do Home Adaptations Prevent Falls for Older People? ... Ashley Akbari, Rowena Griffiths, Alice Puchades, Sara Thomas ...
Background and ObjectivesSARS-CoV-2 infection in children and young people (CYP) can lead to life threatening conditions including COVID-19, transmission to more vulnerable individuals, or even long COVID. Vaccination against COVID-19 reduces the chance of infection and transmission of the virus, but vaccine uptake in the UK has been shown to decrease with age. ApproachWe undertook a multistate-model approach to estimate hazard ratios on national cohorts constructed from linked health and administrative data, adjusting for several demographic factors. The models were applied to 3,433,483 CYP aged 5-17 years between 4th August 2021 and 31st May 2022. The results were combined in a random effects meta-analysis. ResultsUptake of the first COVID-19 vaccine in CYP was lower compared to older age groups in the UK, and diminished further with subsequent doses (34%, 20% and 2% for 1st, 2nd, and booster dose respectively). Age of the CYP and vaccination status of the adults in the household were identified as important risk factors. For example, 5-11-year-olds were less likely to receive their first vaccine compared to 16-17-year-olds (adjusted Hazard Ratio [aHR]: 0.10 (95%CI: 0.06-0.19), and CYP in unvaccinated households were less likely to receive their first vaccine compared to partially vaccinated households (aHR: 0.19, 95%CI 0.13-0.29). Conclusions and Implications Our work hig...
